Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

Prostate cancer is a malignant tumor caused by the malignant proliferation of epithelial cells, which is highly heterogeneous and drug-resistant, and neuroendocrine prostate cancer (NEPC) is an essential cause of drug resistance in its late stage. Elucidating the evolution of NEPC and the resistance...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhe Zhu, Wenjing Xuan, Chaohui Wang, Chancan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1481777/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850129338939211776
author Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li
author_facet Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li
author_sort Zhe Zhu
collection DOAJ
description Prostate cancer is a malignant tumor caused by the malignant proliferation of epithelial cells, which is highly heterogeneous and drug-resistant, and neuroendocrine prostate cancer (NEPC) is an essential cause of drug resistance in its late stage. Elucidating the evolution of NEPC and the resistance process of enzalutamide, a novel antiandrogen, will be of great help in improving the prognosis of patients. As a research hotspot in the field of molecular biology in recent years, the wide range of biological functions of long noncoding RNAs (lncRNAs) has demonstrated their position in the therapeutic process of many diseases, and a large number of studies have revealed their critical roles in tumor progression and drug resistance. Therefore, elucidating the involvement of lncRNAs in the formation of NEPCs and their interrelationship with enzalutamide resistance may provide new ideas for a deeper understanding of the development of this disease and the occurrence of enzalutamide resistance and give a new direction for reversing the therapeutic dilemma of advanced prostate cancer. This article focuses on lncRNAs that regulate enzalutamide resistance and the neuroendocrine transition of prostate cancer through epigenetic, androgen receptor (AR) signaling, and non-AR pathways that act as “molecular sponges” interacting with miRNAs. Some insights into these mechanisms are used to provide some help for subsequent research in this area.
format Article
id doaj-art-9306f1e5a6ad4af896c3f9f41cb99ca8
institution OA Journals
issn 2234-943X
language English
publishDate 2024-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-9306f1e5a6ad4af896c3f9f41cb99ca82025-08-20T02:33:01ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.14817771481777Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancerZhe Zhu0Wenjing Xuan1Chaohui Wang2Chancan Li3Department of Urology, Anhui No.2 Provincial People’s Hospital, HeFei, ChinaDepartment of Obstetrics, Anhui No.2 Provincial People’s Hospital, HeFei, ChinaDepartment of Thyroid and Breast Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, ChinaDepartment of Urology, Anhui No.2 Provincial People’s Hospital, HeFei, ChinaProstate cancer is a malignant tumor caused by the malignant proliferation of epithelial cells, which is highly heterogeneous and drug-resistant, and neuroendocrine prostate cancer (NEPC) is an essential cause of drug resistance in its late stage. Elucidating the evolution of NEPC and the resistance process of enzalutamide, a novel antiandrogen, will be of great help in improving the prognosis of patients. As a research hotspot in the field of molecular biology in recent years, the wide range of biological functions of long noncoding RNAs (lncRNAs) has demonstrated their position in the therapeutic process of many diseases, and a large number of studies have revealed their critical roles in tumor progression and drug resistance. Therefore, elucidating the involvement of lncRNAs in the formation of NEPCs and their interrelationship with enzalutamide resistance may provide new ideas for a deeper understanding of the development of this disease and the occurrence of enzalutamide resistance and give a new direction for reversing the therapeutic dilemma of advanced prostate cancer. This article focuses on lncRNAs that regulate enzalutamide resistance and the neuroendocrine transition of prostate cancer through epigenetic, androgen receptor (AR) signaling, and non-AR pathways that act as “molecular sponges” interacting with miRNAs. Some insights into these mechanisms are used to provide some help for subsequent research in this area.https://www.frontiersin.org/articles/10.3389/fonc.2024.1481777/fulllong noncoding RNAenzalutamideenzalutamide resistanceneuroendocrine prostate cancerARprostate cancer
spellingShingle Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li
Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
Frontiers in Oncology
long noncoding RNA
enzalutamide
enzalutamide resistance
neuroendocrine prostate cancer
AR
prostate cancer
title Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
title_full Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
title_fullStr Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
title_full_unstemmed Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
title_short Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
title_sort long noncoding rna mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
topic long noncoding RNA
enzalutamide
enzalutamide resistance
neuroendocrine prostate cancer
AR
prostate cancer
url https://www.frontiersin.org/articles/10.3389/fonc.2024.1481777/full
work_keys_str_mv AT zhezhu longnoncodingrnamediatesenzalutamideresistanceandtransformationinneuroendocrineprostatecancer
AT wenjingxuan longnoncodingrnamediatesenzalutamideresistanceandtransformationinneuroendocrineprostatecancer
AT chaohuiwang longnoncodingrnamediatesenzalutamideresistanceandtransformationinneuroendocrineprostatecancer
AT chancanli longnoncodingrnamediatesenzalutamideresistanceandtransformationinneuroendocrineprostatecancer